Viral Vector Production (Research-use) Market | USD 7.62 Billion by 2034
The viral vector production (research-use) market size was exhibited at USD 1.95 billion in 2024 and is projected to hit around USD 7.62 billion by 2034, growing at a CAGR of 14.6% during the forecast period 2024 to 2034.
-Market.jpg "Viral Vector Production (Research-use) Market Size 2024 To 2034")
| Report Coverage | Details |
| Market Size in 2025 | USD 2.23 Billion |
| Market Size by 2034 | USD 7.62 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 14.6% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Vector Type, Workflow, Application, End use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | Merck KGaA; Lonza; FUJIFILM Diosynth Biotechnologies.; Cobra Biologics Ltd; Thermo Fisher Scientific, Inc.; Waisman Biomanufacturing; Genezen; YPOSKESI, Inc; Advanced BioScience Laboratories, Inc. (ABL, Inc); Novasep Holdings SAS; Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.); Vigene Biosciences, Inc. |
The increased focus on advanced therapy research has led to the widespread use of viral vectors in the research domain. Furthermore, the COVID-19 pandemic has further stimulated investment in developing vaccines against highly contagious diseases.
In pre-pandemic times, the research communities have been focusing extensively on viral vectors for their effectiveness in gene and cell therapies. However, with the emergence of the COVID-19 outbreak, the application of viral vectors shifted towards vaccine production. Additionally, developers of technology and platforms are actively working towards streamlining the manufacturing process, aiming to overcome the challenges related to scale and efficiency in viral vector production.
The market is influenced by the rising occurrence of genetic disorders, cancer, and infectious diseases, the growing number of clinical studies, and the availability of funding for gene therapy development. Additionally, there is potential for novel drug delivery approaches. The manufacturing services are expected to encounter hindrances in the form of high costs associated with advanced therapies and the technological challenges related to financial sustainability. Nevertheless, the market for viral vector production is projected to witness significant growth during the forecast period. This growth can be attributed to improved clinical outcomes and favorable regulatory bodies, despite the numerous challenges faced.
The adeno-associated virus (AAV) segment accounted for a leading position with a market share of 23.6% in 2024. The major applications of AAV vectors include vaccinology, genome editing, and gene therapy. Clinical research on adeno-associated viruses has been significant in the past few years. The growing number of emerging players and a robust pipeline for vaccines and gene therapies focused on vaccine development have fueled the segment growth. The participation of various universities and clinical institutes for research in gene therapy contributes to the development.
The lentivirus vectors are expected to grow faster at a CAGR of 16.2% in the forecast period. The widespread applications of lentivirus vectors include regenerative medicine, treatment of genetic disorders, and cancer immunotherapy. These are the most commonly used vector types in clinical research. Therefore, their efficiency and versatility in gene therapy are significant to the clinical trials.
The gene and cell therapy development segment accounted for a leading position at the market share of 27.5% in 2024. Gene and cell therapy has experienced a rapid evolution in the past few years. The number of clinically approved vaccines driven by viral vectors is growing due to the high success in clinical and preclinical studies. Extensive research has been conducted on viral vectors in different animal models, leading to the exploration of various viruses as vaccine vectors with high clinical success. Adeno-associated viruses and lentivirus are among the popular choices for vaccine development due to their ability to trigger immune responses against antigens.
The vaccine development segment is expected to witness a fast-growing CAGR of 14.1% in the forecast period. Viral vector is an extremely crucial stage in vaccine development and an interest in production technologies is driven by the regulatory approvals in gene therapy and vaccines. The large clinical pipeline for drug development significantly focuses on AAV and lentiviruses. The use of AAV has grown to a larger extent in cell and gene therapy in the past few years. Therefore, vaccine development is focused on production scale and efficiency.
The downstream processing segment held a leading revenue share of 53.0% in 2024. With the rising demand for vectors in gene and cell therapy production, it is imperative to prioritize the processing and supply of viral vectors in the research setting to maintain product quality and maximize output. As a result, companies are actively assessing advanced platforms to overcome manufacturing bottlenecks and optimize their operations.
-Market-Share,-By-Workflow-2024.jpg "Viral Vector Production (Research-use) Market Share, By Workflow 2024 (%)")
The upstream processing is expected to register a fast-growing CAGR of 14.3% in the forecast period. The upstream process encompasses a series of crucial phases that are significant to the success of viral vector production. It forms the basis for the production process, directing to the point where viral vectors are harvested from host cells. The objective of upstream processing is to optimize the conditions for the host and substantially produce viral vectors. The segment growth is attributed to the significance of upstream processing in gene therapies. Moreover, technological advancements, increasing investments, and partnerships encourage the demand for upstream processing in the forthcoming years.
The pharmaceutical and biopharmaceutical segment accounted for the largest revenue share of 17.4% in 2024. The growing number of pharmaceutical players can be attributed to the significance of research in gene therapies. The contribution of the research community in developing advanced treatments for a range of genetic and acquired diseases is paramount to clinical success.
The emergence of the COVID-19 pandemic has prompted the scientific community to redirect their efforts towards expediting the development of a vaccine against this infectious disease. There has been a surge in the demand for viral vectors from various research institutions. In addition to combating COVID-19, researchers are actively involved in vaccine research and development for diseases such as HIV and Hepatitis B. Developing biotechnology and pharmaceutical companies are currently focused on advancing gene and cell therapies for numerous severe diseases. Biopharmaceutical companies are highly engaged in the Research and Development of viral vectors for therapeutic production.
North America viral vector production (research-use) market accounted for 46.9% in 2024. The market growth is attributed to an increasing number of advanced therapy products in clinical trials for vaccine production. In addition, the demand for viral vectors is high owing to the rapid need for viral vector based vaccines that cater to several life-threatening diseases. Viral vectors are used in clinical research, vaccine development, and biomedical research for cancer treatment and several other diseases. Moreover, there is a growing need for gene therapy and research and development in advanced therapies.
Europe Viral Vector Production (Research-use) Market Trends
Europe viral vector production (research-use) market is poised to grow at a rapid CAGR of 13.7% in the forecast period. The growing emphasis on gene therapy and vaccines is expected to remain vital for the clinical industry in Europe. Viral vectors have shown significant results in preclinical studies for treating diseases such as HIV/AIDS and Hepatitis C. These studies have demonstrated successful feasibility studies against Ebola and Influenza as these vaccines deliver viral DNA into cells, that trigger an immune response.
Asia Pacific Viral Vector Production (Research-use) Market Trends
Asia Pacific viral vector production (research-use) market is expected to witness substantial growth in the forecast period. This is attributed to the rising incidences of target conditions, diseases, and the effectiveness of viral vectors in gene therapy. The availability of private funding for research projects for the advancement of gene therapy is expected to boost the regional market growth. The ongoing research and development on genes and cell therapies dependent on viral vectors fuels the market growth. Moreover, high levels of engagement in public-private partnerships directed at research and manufacturing is expected to boost the need for viral vectors in the region.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the viral vector production (research-use) market
Vector Type
Application
Workflow
End Use
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers